MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

NxStage Medical Company Profile (NASDAQ:NXTM)

Consensus Ratings for NxStage Medical (NASDAQ:NXTM) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.00 (66.95% upside)

Analysts' Ratings History for NxStage Medical (NASDAQ:NXTM)
Show:
DateFirmActionRatingPrice TargetActions
8/7/2015Canaccord GenuityReiterated RatingBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015Canaccord GenuityBoost Price TargetBuy$24.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2014Canaccord GenuityReiterated RatingBuy$20.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Piper JaffrayBoost Price Target$16.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Canaccord GenuityBoost Price TargetBuy$19.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2014Canaccord GenuityReiterated RatingBuy$21.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2014Wells Fargo & Co.DowngradeMarket Perform -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2014Jefferies GroupBoost Price Target$13.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2014Leerink SwannBoost Price Target$15.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2014Canaccord GenuityBoost Price Target$18.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2013Piper JaffrayLower Price TargetOverweight$16.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2013Jefferies GroupLower Price TargetBuy$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2013Canaccord GenuityBoost Price TargetBuy$17.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/31/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha